96744-75-1
96744-75-1 structure
- Name: U-69593
- Chemical Name: Tryptophan-P-1
- CAS Number: 96744-75-1
- Molecular Formula: C22H32N2O2
- Molecular Weight: 356.50
- Catalog: Signaling Pathways GPCR/G Protein Opioid Receptor
- Create Date: 2018-10-06 17:39:16
- Modify Date: 2025-08-24 21:07:38
-
U-69593 is a potent and selective κ1-opioid receptor agonist[1]. U-69593 attenuates cocaine-induced behavioral sensitization in the rat[2]. U-69593 reduces anxiety and enhances spontaneous alternation memory in mice[3]. U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum[4].
| Name | Tryptophan-P-1 |
|---|---|
| Synonyms |
Trp-1
Trytophan pyrolysate 1 1,4-Dimethyl-9H-pyrido(4,3-b)indol-3-amine [3H]-Trp-P-1 Tryptophan P1 [14C]-Trp-P-1 Trp-P-1 3-AMINO-1,4-DIMETHYL-5H-PYRIDO(4,3-B)INDOLE U-69593 |
| Description | U-69593 is a potent and selective κ1-opioid receptor agonist[1]. U-69593 attenuates cocaine-induced behavioral sensitization in the rat[2]. U-69593 reduces anxiety and enhances spontaneous alternation memory in mice[3]. U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum[4]. |
|---|---|
| Related Catalog | |
| In Vivo | U-69593 (0.16 mg/kg; s.c.) attenuates cocaine-induced behavioral sensitization in the rat[2]. U-69593 (1, 10, 25 nmol/µL; Microinjection) reduces anxiety and enhances spontaneous alternation memory in mice[3]. U-69593 (0.32 mg/kg; s.c.) decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum[4]. Animal Model: Rat[2] Dosage: 0.16 mg/kg Administration: S.c. (an acute injection of cocaine (20 mg/kg i.p.)) Result: Attenuated the acute and chronic effects of cocaine on locomotor activity and stereotypy. Animal Model: CD-1 mice[3] Dosage: 1, 10, 25 nmol/µL Administration: Microinjection (in the infralimbic cortex (IL)), once every week, 2 weeks Result: Dose-dependently prolonged transfer-latency (T-L) and produced a dose-dependent anxiolytic behavioural profile, and after 24 h, the mouse were observed small but detectable carry-over effects. In week 2, U-69593 dose-dependently prolonged T/L and produced an anxiolytic behavioural profile in the first EPM (elevated plus-maze) trial, but observed a robust anxiolytic behavioural profile. Animal Model: 280-350 g, male Wistar rats[4] Dosage: 0.32 mg/kg Administration: S.c. (followed 15 min later by an injection of amphetamine (2.5 mg/kg i.p.)) Result: Significantly reduced the amphetamine-stimulated increase in dialysate dopamine levels and blocked the ability of amphetamine to evoke an increase in dialysate glutamate levels. |
| References |
| Density | 1.14g/cm3 |
|---|---|
| Boiling Point | 518.719ºC at 760 mmHg |
| Molecular Formula | C22H32N2O2 |
| Molecular Weight | 356.50 |
| Flash Point | 267.512ºC |
| Exact Mass | 356.24600 |
| PSA | 32.78000 |
| LogP | 3.19150 |
| Index of Refraction | 1.581 |
| Storage condition | 2-8°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |